Samsung Bioepis Co., Ltd. and Organon & Co. announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration...
Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara® (ustekinumab)....
Joint study by University of Shizuoka, Kobe University, and Noster Inc. uncovers a novel postbiotic pathway for obesity prevention.A new collaborative study from the University of Shizuoka, Kobe University, and Kyoto-based biotech company Noster...
Kimera Labs, Inc., the pioneer in therapeutic exosome biotechnology, is proud to announce its selection as a semifinalist in the prestigious $101 million XPRIZE Healthspan competition. This milestone recognizes Kimera's groundbreaking work in...
Rein Therapeutics a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that the RENEW Phase 2 trial of its lead asset,...
INBRAIN Neuroelectronics, a clinical-stage neurotechnology company developing precision brain-computer interfaces (BCIs) powered by graphene, announced it has been awarded a €4 million grant by the Spanish Ministry of Industry and Tourism through...
NImmune Biopharma a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases, will present...
SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for cancer and disorders of the central nervous system (CNS), announced the...
Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National...
Xencor, Inc.a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942. A high-potency,...
Bold Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel oncology treatments, announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, will be presenting a late-breaking poster on BOLD-100's potent...
Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial...
Creyon Bio, Inc. announced the appointment of industry leader, Serge Messerlian as Chief Executive Officer, effective immediately. Mr. Messerlian brings Creyon Bio a track record in both multinational pharmaceutical and biotechnology leadership as...
TNF Pharmaceuticals, Inc. a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify...
Toenail fungus, medically known as onychomycosis, is more than just a cosmetic issue. It's a persistent condition that affects the appearance, health, and comfort of your feet. What begins as a small yellow or white spot under the nail can...
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer and other diseases, announced today it has filed two investigational new drug (IND) applications (HF158K1 and HFK2) with China’s National Medical...
Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company, announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol's potential in overcoming drug resistance in gastrointestinal...
Bruker Corporation today announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon...
Chime Biologics, a leading global CDMO that enables its partners' success in biologics, is pleased to announce a strategic cooperation agreement with Polpharma Biologics to advance the end-to-end development and manufacture of a biosimilar product...
Exicure, Inc. today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. (“Exicure”) is planning for a clinical trial in Acute Myeloid Leukemia (AML) with GPC-100. The company believes that...
